Oncogenic KRAS impairs EGFR antibodies' efficiency by C/EBPβ-dependent suppression of EGFR expression.

S. Derer, S. Berger, M. Schlaeth, T. Schneider-Merck, K. Klausz, S. Lohse, M. Overdijk, M. Dechant, C. Kellner, I. Nagelmeier, A.H. Scheel, J.J. Lammerts van Bueren, J.G. van de Winkel, P.W.H.I. Parren, M. Peipp, T. Valerius

Research output: Contribution to journalArticleAcademicpeer-review

Original languageUndefined/Unknown
Pages (from-to)190-205
Number of pages16
JournalNeoplasia
Volume14
Issue number3
Publication statusPublished - 2013

Cite this